Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $46.6 million.

  • Ironwood Pharmaceuticals' Operating Expenses fell 2938.32% to $46.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.8 million, marking a year-over-year decrease of 2270.7%. This contributed to the annual value of $258.3 million for FY2024, which is 8139.37% down from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Operating Expenses stood at $46.6 million, which was down 2938.32% from $39.9 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Operating Expenses registered a high of $1.2 billion during Q2 2023, and its lowest value of $38.6 million during Q3 2021.
  • Its 5-year average for Operating Expenses is $112.9 million, with a median of $46.6 million in 2025.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Operating Expenses surged by 276348.13% in 2023 and then plummeted by 9416.9% in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Operating Expenses (Quarter) stood at $60.5 million in 2021, then crashed by 35.85% to $38.8 million in 2022, then surged by 105.9% to $80.0 million in 2023, then decreased by 26.15% to $59.1 million in 2024, then fell by 21.13% to $46.6 million in 2025.
  • Its Operating Expenses was $46.6 million in Q3 2025, compared to $39.9 million in Q2 2025 and $70.3 million in Q1 2025.